Weil Company Inc. Cuts Holdings in United Therapeutics Co. (NASDAQ:UTHR)

Weil Company Inc. lessened its position in shares of United Therapeutics Co. (NASDAQ:UTHR) by 89.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,272 shares of the biotechnology company’s stock after selling 10,531 shares during the period. Weil Company Inc.’s holdings in United Therapeutics were worth $449,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Wealth Enhancement Advisory Services LLC grew its holdings in shares of United Therapeutics by 0.8% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 4,913 shares of the biotechnology company’s stock worth $1,761,000 after purchasing an additional 39 shares during the period. MBM Wealth Consultants LLC lifted its position in United Therapeutics by 1.9% during the fourth quarter. MBM Wealth Consultants LLC now owns 2,151 shares of the biotechnology company’s stock valued at $775,000 after buying an additional 41 shares in the last quarter. UMB Bank n.a. grew its stake in United Therapeutics by 4.9% during the fourth quarter. UMB Bank n.a. now owns 1,101 shares of the biotechnology company’s stock worth $388,000 after buying an additional 51 shares during the period. Access Investment Management LLC grew its stake in United Therapeutics by 0.8% during the fourth quarter. Access Investment Management LLC now owns 7,335 shares of the biotechnology company’s stock worth $2,588,000 after buying an additional 55 shares during the period. Finally, MassMutual Private Wealth & Trust FSB increased its position in shares of United Therapeutics by 31.9% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company’s stock worth $85,000 after acquiring an additional 58 shares in the last quarter. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, Director Nilda Mesa sold 255 shares of the company’s stock in a transaction that occurred on Monday, December 30th. The stock was sold at an average price of $355.77, for a total transaction of $90,721.35. Following the sale, the director now directly owns 5,528 shares of the company’s stock, valued at approximately $1,966,696.56. This represents a 4.41 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Paul A. Mahon sold 7,700 shares of United Therapeutics stock in a transaction on Thursday, December 5th. The stock was sold at an average price of $374.37, for a total transaction of $2,882,649.00. Following the completion of the transaction, the executive vice president now directly owns 36,710 shares of the company’s stock, valued at approximately $13,743,122.70. This represents a 17.34 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 124,164 shares of company stock worth $45,278,893. 11.90% of the stock is currently owned by corporate insiders.

United Therapeutics Price Performance

UTHR opened at $357.50 on Wednesday. United Therapeutics Co. has a 12-month low of $221.53 and a 12-month high of $417.82. The stock has a market capitalization of $15.96 billion, a PE ratio of 15.70, a P/E/G ratio of 0.97 and a beta of 0.57. The firm’s fifty day moving average price is $361.95 and its 200 day moving average price is $361.11.

Analyst Ratings Changes

Several equities analysts recently weighed in on UTHR shares. LADENBURG THALM/SH SH lifted their target price on shares of United Therapeutics from $319.00 to $344.00 and gave the company a “buy” rating in a report on Thursday, October 31st. The Goldman Sachs Group boosted their price objective on United Therapeutics from $243.00 to $302.00 and gave the stock a “neutral” rating in a research note on Friday, November 1st. StockNews.com upgraded United Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Thursday, January 16th. HC Wainwright boosted their price target on United Therapeutics from $400.00 to $425.00 and gave the stock a “buy” rating in a research report on Thursday, October 31st. Finally, Oppenheimer increased their price objective on shares of United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a research report on Thursday, October 31st. One investment analyst has rated the stock with a sell rating, two have given a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $388.25.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.